The term pemphigus refers to a group of uncommon diseases characterized by the formation of intra-epidermal blisters. Pemphigus vulgaris usually results in extensive involvement of the skin which is not difficult to diagnose. In pemphigus foliaceus, blistering is less pronounced because lesions are more superficial and extremely fragile: leafy scales and crusts predominate. The rash often begins on the scalp, face and trunk and may resemble seborrheeic dermatitis. Remissions occur, but usually the rash extends and may eventually involve the whole body surface. The diagnosis is established histologically by the presence of acantholysis (separation of epidermal cells) predominantly in the upper epidermis supported by the demonstration of epithelial antibody in the serum (Chorzelski & Beutner 1969 , Rook et al. 1972 .
Pemphigus associated with penicillamine therapy was first reported in France, initially in Wilson's disease (Degos et a!. 1969 ) and later in rheumatoid arthritis ). Both pemphigus foliaceus and pemphigus vulgaris have been described, usually improving when the drug is stopped; in a few cases, however, the rash persists. Dermatologists in Great Britain are now aware of this side-effect (Cairns 1976 ; J S Pegum, case presented to Royal Society of Medicine, Section of Dermatology, 18 March 1976) .
At the Rheumatology Departments of the Nuffield Orthopedic Hospital, Oxford, and Stoke Mandeville Hospital, Aylesbury, 168 patients with arthritis have been given penicillamine for over six months. This study presents 8 who developed an itchy eruption following 6-12 months of therapy. In 3 patients blisters were present at the onset whereas the others had nonspecific scaly lesions and were thought to have the 'late penicillamine rash'. Three were referred to dermatologists when the rash became more extensive in spite of stopping penicillamine and a diagnosis of pemphigus foliaceus was established in each case. The eruption cleared in 6 patients and did not return in 2 when penicillamine was reintroduced. Pemphigus remains active in 2 patients, however, and the serious implications of this are discussed.
Case 1
In March 1974, a man aged 51 with seropositive rheumatoid arthritis was started on penicillamine 250 mg daily while taking 5 mg prednisolone daily. He had previously been treated with salicylates and a course of gold. Shortly afterwards he developed urticaria which cleared spontaneously. In the second month the dose was increased to 500 mg daily and a month later to 750 mg daily. Seven months after starting penicillamine, he developed an itchy eruption on the trunk consisting of erythematous lesions with marked peripheral scaling which was considered to be the 'late penicillamine rash'. The drug was stopped and the rash had almost cleared four months later. While he was on holiday in Teneriffe it became more extensive, and for the first time blisters were seen. On his return in April 1975, a diagnosis of pemphigus foliaceus was made. Skin biopsy showed a subcorneal blister, but acantholysis was not seen (Fig 1) . In the dermis there was a moderate perivascular infiltration of neutrophils. Direct immunofluorescence (IMF) was not performed, but indirect IMF, with guinea-pig lip and monkey oesophagus, showed the presence of circulating antibody to intercellular substances to a titre of 1 in 10.
Initially the rash was only partially controlled by 80 mg of prednisolone daily, but later it improved and the dose of prednisolone was slowly reduced. Azathioprine 150 mg daily was also given but discontinued because of vomiting. The patient is currently taking prednisolone 25 mg daily, and has extensive lesions on the trunk and scalp.
Case 2 (Presented to the Royal Society of Medicine, Section of Dermatology, 19 February 1976) In November 1974, a female aged 46 with a 13-year history of seropositive rheumatoid arthritis poorly controlled by prednisolone and one course of gold, was given penicillamine 250 mg daily. The dose was increased at monthly intervals by 250 mg to 750 mg daily. The drug was withdrawn in July 1975, when an itchy eruption, thought to be the 'late penicillamine rash', appeared on the abdomen; lesions consisted of scaly plaques, some with tiny central or peripheral vesicles. The rash, uncontrolled by 15 mg prednisolone daily, slowly spread to the chest, and after five months, numerous small blisters suddenly appeared on the trunk, scalp and face ( Fig 2) . It was at this time that a diagnosis of pemphigus foliaceus was made. Histology of an early lesion showed a subcorneal blister with moderate acantholysis and a perivascular infiltrate of lymphocytes and neutrophils in the dermis (Fig 3) .
Direct IMF of paralesional skin was negative; indirect IMF, with guinea-pig lip and monkey aesophagus, demonstrated antibody to intercellular substance in the serum to a titre of 1 in 10. Antinuclear factor (ANF) was positive.
Blistering was controlled by increasing the dose of prednisolone to 60 mg daily, lesions healing with hyperpigmentation. New lesions continue to appear and the patient is currently taking prednisolone 20 mg and azathioprine 150 mg daily and applying clobetasol propionate ointment (Dermovate) topically.
Case 3
In September 1974, a woman aged 65 with seropositive rheumatoid arthritis and digital vasculitis was started on penicillamine 250 mg daily. The dose was increased Fig 2 Case 2 Crusted andscaling lesions with small blisters to 500 mg daily after one month and 750 mg daily a month later. At the time penicillamine treatment was begun she was also taking prednisolone 7.5 mg daily, indomethacin and analgesics; previous therapy had included a course of gold.
In May 1975, she developed the familiar 'late rash' with a few scaly, itchy lesions on the neck, apparently induced by friction. Mouth ulcers were present at this time, but resolved with local steroids. Penicillamine was discontinued in June 1975, following a Mediterranean holiday, when the rash became more extensive with obvious blistering.
A clinical diagnosis of pemphigus folicaceus was not confirmed by histology, since a relatively old lesion was biopsied and showed epidermal ulceration with infiltration of dermis by neutrophils. It was supported, however, by direct IMF of paralesional skin which demonstrated IgG and IgM in intercellular spaces. The serum was not examined for epithelial antibody at this time. ANF was positive.
The eruption was treated with fluocinolone acetonide (Synalar) and rapidly healed. In November 1975 the patient developed digital gangrene, and penicillamine was restarted at a dose of 125 mg daily. By the fourth month she was taking 750 mg daily with marked improvement and no recurrence of the rash. Epithelial antibody was detected in the serum to a titre of 1 in 10 in April 1976, nine months after the disappearance of the rash. In April 1975, a 59-year-old woman with a two-year history of seropositive rheumatoid arthritis responding poorly to indomethacin, gold and prednisolone, was started on penicillamine 500 mg daily. In January 1976, an itchy and painful eruption appeared on the scalp and trunk; lesions began as small blisters which dried up and became scaly. The rash was reported two months later when a diagnosis of pemphigus foliaceus was made and the penicillamine discontinued.
Skin biopsy of an intact lesion present for two days showed a subcorneal blister but no acantholysis. There was a moderate perivascular infiltrate. Antibody to intercellular epidermal material was present in the serum to a titre of 1 in 10. Direct IMF was negative. Circulating IgG complexes were detected by Sepharose 6 B filtration studies.
Itching was helped by topical 0.2% fluocinolone acetonide (Synalar Forte), and three months later the skin was free of lesions.
Case 5 (Presented to the Royal Society of Medicine, Section of Dermatology, 21 October 1976) A man aged 57 with mild psoriasis since childhood developed seronegative polyarthritis in January 1975 which did not respond to phenylbutazone and prednisolone 5 mg daily. In November 1975 he was started on penicillamine 250 mg daily which was slowly increased to 1 g daily. After seven months the psoriasis disappeared and was replaced by an intensely itchy widespread eruption with small tense blisters. Large areas of erythema were present on the lower legs, and annular urticarial lesions on the trunk and arms.
A clinical diagnosis of dermatitis herpetiformis was made but not supported by histological or immuno-fluorescence findings. A skin biopsy showed intraepidermal vesicles, containing a few neutrophils, with adjacent spongiosis. There was a moderate dermal perivascular infiltrate of lymphocytes and neutrophils. Direct IMF was negative. In view of the presence of circulating epithelial antibody in high titre (1 in 160) the patient was considered to have pemphigus.
Penicillamine was discontinued and one month later the rash had cleared.
Cases 6-8 Three patients (2 females and one male) aged 58-61 years, with seropositive rheumatoid arthritis, developed an itchy rash after taking penicillamine for 6-12 months. Initially they were given 250 mg daily, and this was increased by 250 mg at monthly intervals to 750 mg daily. All 3 were receiving analgesics, and 2 were receiving systemic corticosteroids. Lesions appeared mainly on the trunk but also on the legs and face. Annular scaly lesions were present in 2 patients, whereas the third had small blisters which turned rapidly into crusts. This patient was suspected of having pemphigus, but histology of a relatively old lesion was unhelpful.
A diagnosis of 'late penicillamine rash' was made in all three patients, and within eight weeks of stopping the drug they were free of lesions. Colour photographs were taken of each patient at the onset of the eruption and subsequently examined by French and British dermatologists who considered that they were compatible with a diagnosis of pemphigus foliaceus (meeting of the Dowling Club, June 1976, Clinique Tarnier, Paris).
Penicillamine was restarted in one patient without recurrence of the rash. The drug was eventually withdrawn because of thrombocytopenia, and eighteen months later the patient died from the Goodpasture syndrome.
Discussion
Rashes are common during penicillamine therapy, although the incidence and probably the type of lesion seen varies with the disease that is being treated. Up to 60% of patients with Wilson's disease and cystinuria (Walshe 1968 , Scheinberg 1968 , Crawhall & Watts 1968 ) may be affected, whereas in rheumatoid arthritis, where lesser doses are prescribed, the incidence is much lower (12-25 %) (Huskisson & Mowat 1975) .
Early urticarial or macular eruptions are commonest, but rarely lead to permanent withdrawal of the drug. The blisters, scars and bruises on pressure areas which are seen in Wilson's disease and cystinuria, after one year of treatment, are probably related to the lathyrogenic action of penicillamine on dermal collagen (Katz 1967 , Beer & Cooke 1967 .
A very different scaly, itchy 'late eruption' is described by rheumatologists; this appears after six 'months of therapy (Huskisson & Mowat 1975) ; 5 of our patients presented with such lesions. The findings in 3 of them, who later developed blisters, suggest that the late penicillamine eruption may be pemphigus foliaceus. The histological appearance of the late penicillamine eruption has been described by Huskisson (1976) as dermatitis-like. However, similar nonspecific changes are often found in pemphigus foliaceus when biopsies are taken later than 24 hours.
The clinical features of Case 5, who had circulating epithelial antibody, resembled dermatitis herpetiformis; Hewitt et al. (1975) described such a case. It is well known that pemphigus foliaceus may begin with a dermatitis herpetiformis-like eruption, and histology in these atypical cases often shows spongiosis, similar to that found in our patient (Knight et al. 1976 , Osteen et al. 1976 ).
The cause of pemphigus is unknown, but an immune mechanism seems likely since antibody to intercellular epidermal material is regularly found in the serum. The association of pemphigus with myasthenia gravis and lupus erythematosus supports this. The sulphydryl group in penicillamine could bind to or cleave intercellular cement substances (a proteoaminoglycan) with resulting antibody formation. Furthermore, in those patients with a rash which persists long after discontinuing penicillamine, the perpetuating factor is presumably immunological. There is, however, no evidence to suggest that patients with rheumatoid arthritis, in the absence of penicillamine, are predisposed to pemphigus. Antibody titres in most of our patients and in those of Hewitt et al. (1975) tended to be low, even in the presence of extensive lesions. This contrasts with spontaneous pemphigus, where levels correlate with disease activity and may be used to predict relapses and remissions. Pemphigus induced by drugs appears to be rare, but phenylbutazone, rifampicin and levamisole have been incriminated (Gange et al. 1976 , Beutner et al. 1970 , Huskisson 1976 ).
Pemphigus has a poor prognosis, and the persisting rash in 2 of our patients, 15 months and two years after stopping the drug, is worrying. The death rate from pemphigus foliaceus was 60% before the introduction of steroid therapy, and unfortunately morbidity and mortality remain high, since 120-200 mg prednisolone daily may be required to control severe cases, followed by maintenance doses in excess of 20 mg daily (Perry & Brunsting 1965) . Milder cases, such as cases 3 and 4, respond to topical steroids alone. Benveniste et al. (1975) examined the sera of 40 patients with rheumatoid arthritis who had been treated with penicillamine for over six months, and were unable to detect epithelial antibody in any of them. Further studies are needed, however, to determine whether pemphigus can be prevented in patients taking penicillamine, by screening them for epithelial antibody. Dr H E Amos (Carshalton): May ask Dr Marsden to clarify a few points. He said that 4 patients were examineddoes that mean that some patients were seen without the epithelial antibody, but who had the histological features of pemphigus ? Exactly what sort of titre levels are involved ?
Dr Marsden: We have 8 patients in all. Epithelial antibody was found in 5 of them. It has not been looked for in 3 patientsthe 3 seen by Dr Hillin whom the rash subsided and whose investigations are not complete. When looked for, however, epithelial antibody has been found in all patients.
Dr Amos: At what sort of level?
Dr Marsden: Very low titres, about 1:10, with the exception of one patient in whom a titre of 1:160 was recorded.
Dr Amos: If a number of normal individuals are examined, low levels of epithelial antibody are found. I wonder how sure one can be that the low levels of anti-epithelial antibody which you detect relate specifically to penicillamine administration ? Dr Marsden: This was done in 2 patients and was found to be negative. We were not surprised at this because in a small number of patients with pemphigus direct immunofluorescence can be negative.
Dr Holti: Usually, the diagnosis of pemphigus is not accepted unless this test is positive. The druginduced blistering eruptions which remit spontaneously when the drug is stopped are unlike the true entity of pemphigus foliaceus. I entirely agree that circulating antibody to epithelial cells is found in burns patients, or in patients who have sustained other extensive damage to the epithelial layers of their skin. We are probably dealing here with a drug-induced eruption which mimics pemphigus foliaceus, but it clearly has a different prognosis.
Those rashes which continuedtwo or three, I thinkmay of course be true pemphigus foliaceus in patients whose disease had been latent and was 'brought out' by penicillamine therapy.
Dr E J Moynahan (London): I agree with Dr Holti, first, in that none of the pictures shown by Dr Marsden resembles pemphigus foliaceus.
To reinforce what Dr Holti has said, may I add that the same situation is arising now with the ,-blockers and psoriasiform eruptions. Those patients who have a tendency to psoriasis may develop widespread psoriasis which may persist for a long time afterwards. This is not surprising as ,8-blockade reduces the level of 3'5'-AMP within the cell and thereby takes the brake off cell division, as it were, in the tachymitotic epidermis of the psoriatic. Penicillamine may act likewise in the few patients predisposed to pemphigus, but any blistering is more likely to result from interference with the cross-linking of collagen, thus mimicking the natural disorder (nosomimesis as distinct from nosogenesis). Dr Marsden: The antigen is probably intercellular cement substancewhatever that is. It is thought to be a proteoaminoglycan.
Dr Beam: Is it, then, an antibody to mucopolysaccharide? Can it be absorbed out with pure mucopolysaccharide?
Dr Marsden: I do not think that this has been done.
Dr Beam: How disease specific is this antibody?
Dr Marsden: As I have already said, with the exception of burns, &c., it seems to be specific to pemphigus.
Dr Beam: And it can be absorbed out specifically with epithelial cells, but not with endothelial cells? This is certain?
Dr Marsden: Yes, I think so, although I would not profess to be knowledgeable on this aspect.
Dr I H Scheinberg (New York): I have just been conferring with Dr Walshe. Between us we have probably seen about 400 or 500 patients with Wilson's disease who have been treated with penicillamine, but neither of us has ever seen lesions like this on doses of the drug which, if anything, are higher than Dr Marsden's. I bow to the dermatologists' view that it is not classical pemphigus, so it must be something due to the combined effects of rheumatoid arthritis and penicillaminesince it is apparently not seen in rheumatoid alone, and we certainly do not see it in Wilson's disease treated with penicillamine.
It presumably represents some kind of interaction between the drug and the pathochemistry or pathophysiology of rheumatoid arthritis. It must be sui generis, which, I suppose, is why the dermatologists are unhappy about it. Dr Marsden: I agree, except that the first reported case had Wilson's disease. Dr Scheinberg: How well was that case studied, in terms of the rather arbitrary criteria which were applied? We would have to look carefully at it. Dr Marsden: The case of Professor Degos was a florid case of pemphigus and well described.
Dr J-P Camus (Paris): We tried to look for autoantibodies in patients receiving D-penicillamine and who had cutaneous side-effects. We studied 14 patients. In 5 pemphigus patients we found four positive titres of antibody. In 2 patients with atypical rash (not pemphigus) the titres were also positive.
In terms of prevention, clinical prevention is probably more efficient than systematic search for autoantibodies, because the autoantibodies appear when the side-effects are already the problem. Dr G S Crockett (Kettering): How many of these patients had antinuclear factor ? Dr Marsden: Two of them.
